Business Description
Zelira Therapeutics Ltd
ISIN : AU000000ZLD1
Total Employee Number:
8Description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Equity-to-Asset | -3.43 | |||||
Debt-to-Equity | -0.48 | |||||
Debt-to-EBITDA | -0.68 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -104.11 | |||||
Beneish M-Score | 13.21 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 42.7 | |||||
3-Year EPS without NRI Growth Rate | 45.7 | |||||
3-Year FCF Growth Rate | 28.6 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 96.3 | |||||
9-Day RSI | 74.39 | |||||
14-Day RSI | 55.8 | |||||
3-1 Month Momentum % | 5.87 | |||||
6-1 Month Momentum % | 31.58 | |||||
12-1 Month Momentum % | 25.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.11 | |||||
Quick Ratio | 0.02 | |||||
Days Inventory | 41407.22 | |||||
Days Sales Outstanding | 26280 | |||||
Days Payable | 147595.19 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.5 | |||||
Shareholder Yield % | -6.44 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -800 | |||||
Operating Margin % | -380900 | |||||
Net Margin % | -362800 | |||||
EBITDA Margin % | -317200 | |||||
FCF Margin % | -314800 | |||||
OCF Margin % | -314800 | |||||
ROA % | -122.72 | |||||
ROIC % | -78.96 | |||||
3-Year ROIIC % | -32.13 | |||||
ROC (Joel Greenblatt) % | -1665.97 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -2.4 | |||||
EV-to-EBITDA | -2.6 | |||||
EV-to-Revenue | 8254 | |||||
EV-to-FCF | -1.68 | |||||
Price-to-GF-Value | 4.38 | |||||
Earnings Yield (Greenblatt) % | -41.67 | |||||
FCF Yield % | -82.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ZLDAF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Zelira Therapeutics Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.001 | ||
| EPS (TTM) ($) | -0.202 | ||
| Beta | 0.8557 | ||
| 3-Year Sharpe Ratio | 0.2 | ||
| 3-Year Sortino Ratio | 0.55 | ||
| Volatility % | 73.91 | ||
| 14-Day RSI | 55.8 | ||
| 14-Day ATR ($) | 0.000127 | ||
| 20-Day SMA ($) | 0.35 | ||
| 12-1 Month Momentum % | 25.36 | ||
| 52-Week Range ($) | 0.2 - 0.4165 | ||
| Shares Outstanding (Mil) | 11.9 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zelira Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zelira Therapeutics Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.005714:1 Stock Split | 2022-04-14 | 2.26 (+0.00%) |
Show
Entries
Zelira Therapeutics Ltd Frequently Asked Questions
What is Zelira Therapeutics Ltd(ZLDAF)'s stock price today?
The current price of ZLDAF is $0.35. The 52 week high of ZLDAF is $0.42 and 52 week low is $0.20.
When is next earnings date of Zelira Therapeutics Ltd(ZLDAF)?
The next earnings date of Zelira Therapeutics Ltd(ZLDAF) is .
Does Zelira Therapeutics Ltd(ZLDAF) pay dividends? If so, how much?
Zelira Therapeutics Ltd(ZLDAF) does not pay dividend.
Guru Commentaries on OTCPK:ZLDAF
No articles.
Press Release
Articles on Zelira Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers